XML 31 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727
License Agreement/Revenue Recognition - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended
Apr. 30, 2014
Mar. 31, 2015
Ampio [Member] | KOREA    
Revenue Recognition [Line Items]    
Upfront payment received   $ 500,000
Upfront payment received, net proceed   418,000
Milestone payments that may be earned and recognized   $ 3,200,000
Deferred revenue recognition period   10 years
Royalty percentage of net sales   25.00%
Vyrix Pharmaceuticals [Member]    
Revenue Recognition [Line Items]    
Upfront payment received $ 250,000  
Milestone payments that may be earned and recognized $ 3,025,000  
Deferred revenue recognition period 7 years  
Agreement expiration period 15 years